Revuforj (Revumenib Citrate) Patent Expiration, LOE Window & CMS Spending

Revuforj (Revumenib Citrate) by Syndax: FDA Orange Book core substance LOE 2037-06-08 (last listed 2042-12-18), 0 AB generics, $1.1M 2024 CMS Part D & Medicaid spend, and $19,750 CA SB 17 specialty launch WAC.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorSyndax
FDA Application & PathwayN218944 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE Date2037-06-08
Last Listed Patent or Exclusivity Date2042-12-18
Orange Book Patents (*PED Extensions)3 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$1.1M
2024 Medicare Part D Spend$1.1M
2024 Medicaid Spend$0
Reported Wholesale Price Change (CA SB 17)Specialty launch notice ($19,750 intro WAC)